Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alista female sexual dysfunction program

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Vivus initiates Phase III trial of its topical alprostadil Alista for treatment of female sexual arousal disorder, the firm announces Sept. 7. Alprostadil, a synthetic prostaglandin, is the same active ingredient found in the company's male erectile dysfunction product Muse. Vivus expects two to four trials in 1,500-2,000 patients will support the Alista NDA, which will be submitted in late 2006 or in 2007 (1Pharmaceutical Approvals Monthly July 1, 2004, p. 24). The firm also has a testosterone spray slated to enter Phase III in 2005...

You may also be interested in...

P&G’s Intrinsa Priority Review Puts Approval Timeline At Early 2005

Procter & Gamble’s testosterone patch Intrinsa could be approved for female sexual dysfunction by January.

P&G Intrinsa Could Inaugurate Female Sexual Dysfunction Market In 2005

Procter & Gamble’s Intrinsa could be the first treatment for female sexual dysfunction to reach the market, with potential approval as early as 2005.

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts